pcr
assay
markedli
improv
diagnosi
human
rhinovirus
hrv
infect
increas
sensit
comparison
tradit
cell
cultur
howev
mani
rtpcr
protocol
still
timeconsum
realtim
pcr
assay
result
improv
viru
detect
quantif
rapid
quantit
result
repres
import
advantag
diagnost
workup
hrv
infect
could
relev
consid
futur
potenti
avail
antivir
agent
human
rhinovirus
common
viral
agent
human
serolog
type
respons
case
common
cold
associ
upper
respiratori
tract
complic
adult
children
although
hrv
gener
temperatur
restrict
replic
optim
growth
temperatur
observ
tracheobronchi
tree
often
lower
bodi
core
temperatur
also
relat
extern
temperatur
frequenc
ventil
permiss
hrv
replic
moreov
evidenc
mani
hrv
serotyp
replic
effici
core
bodi
temperatur
modest
differ
term
infecti
titr
inde
sever
studi
link
hrv
infect
ill
lower
respiratori
tract
immunocompet
patient
includ
exacerb
preexist
airway
diseas
asthma
chronic
obstruct
pulmonari
diseas
copd
cystic
fibrosi
pneumonia
bronchiol
children
age
year
hospit
hrv
infect
howev
recent
studi
hospit
adult
pulmonari
diseas
found
preval
hrv
bronchoalveolar
lavag
bal
specimen
without
evidenc
signific
differ
preval
relat
presenc
copd
pneumonia
acut
respiratori
ill
contrast
immunocompet
subject
hrv
clearanc
immunocompromis
patient
may
delay
prolong
shed
lead
onset
lifethreaten
condit
chronic
infect
evid
demonstr
hrv
diseas
exclus
limit
upper
airway
may
caus
lower
respiratori
complic
togeth
frequenc
hrv
infect
increas
number
immunocompromis
patient
underlin
need
includ
hrv
virolog
diagnost
acut
lower
respiratori
tract
ill
howev
mani
laboratori
institut
adopt
hrv
diagnost
routin
clinic
use
limit
inform
avail
hrv
clinic
impact
comparison
respiratori
virus
aim
studi
develop
valid
rt
realtim
pcr
assay
quantif
hrv
rna
clinic
sampl
effici
sensit
specif
inter
intraassay
variabl
dynam
rang
determin
fig
prototyp
rhinovirus
obtain
american
type
cultur
collect
atcc
manassa
va
clinic
specimen
origin
virolog
unit
azienda
ospedalierouniversitaria
san
giovanni
battista
turin
includ
bronchoalveolar
lavag
bal
obtain
patient
mf
mean
age
year
rang
bronchoalveolar
lavag
procedur
perform
previous
describ
investig
caus
unexplain
fever
andor
respiratori
symptom
andor
new
infiltr
chest
xray
check
previou
posit
routin
followup
lung
transplant
recipi
process
specimen
thaw
liquefi
nacetylcistein
clinic
specimen
divid
two
group
sampl
immunocompet
individu
ii
immunocompromis
patient
includ
transplant
recipi
patient
condit
chemotherapi
hiv
infect
longterm
use
corticosteroid
discharg
diagnosi
made
accord
intern
classif
version
base
revis
clinic
modif
autom
extract
rna
perform
nuclisen
easymag
platform
marci
l
etoil
franc
rna
extract
volum
clinic
specimen
accord
manufactur
instruct
elut
final
volum
rt
reaction
done
separ
tube
random
cdna
syntesi
extract
rna
two
step
first
reaction
mixtur
contain
random
primer
ngml
invitrogen
mm
dntp
invitrogen
carlsbad
ca
ad
incub
min
use
fast
thermal
cycler
appli
biosystem
monza
itali
subsequ
second
reaction
mixtur
contain
dtt
buffer
nm
ph
nm
kcl
rnase
outtm
invitrogen
revers
transcriptas
superscripttm
ii
rt
invitrogen
give
total
volum
use
incub
min
min
min
cdna
mixtur
use
target
cdna
primer
design
within
highli
conserv
region
hrv
genom
tabl
use
primer
express
softwar
appli
biosystem
cheshir
uk
briefli
cdna
ad
pcr
solut
contain
buffer
mm
unit
recombin
subtherm
dna
polymeras
sic
rome
itali
dntp
sens
antisens
primer
initi
denatur
step
min
firstround
pcr
amplif
carri
follow
condit
cycl
cycl
min
use
fast
thermal
cycler
appli
biosystem
pcr
product
bp
load
onto
wv
agaros
gel
contain
ethidium
bromid
gel
visual
uv
board
pcr
product
clone
use
ptopota
clone
invitrogen
recombin
plasmid
propag
higheffici
chemic
compet
cell
invitrogen
use
heat
shock
procedur
overnight
cultur
select
transform
clone
amplifi
cultur
liquid
lb
medium
g
bactotrypton
g
yeast
extract
mm
nacl
gl
agar
ph
contain
ampicillin
plasmid
dna
extract
purifi
use
wizard
plu
sv
miniprep
dna
purif
system
promega
madison
wi
plasmid
concentr
estim
spectrophotometr
read
dna
copi
number
target
plasmid
calcul
molecular
weight
construct
mw
avogadro
number
target
plasmid
contain
dna
copi
number
determin
sensit
pcr
assay
stock
prepar
dilut
seri
dilut
limit
detect
defin
lowest
concentr
target
quantifi
wherea
effici
rtpcr
assay
also
evalu
defin
neg
control
rnasefre
steril
water
sigma
includ
batch
test
sampl
check
carryov
contamin
reaction
mixtur
contain
master
mix
platinum
qpcr
rox
invitrogen
mm
primer
mm
fam
probe
target
mm
primer
intern
control
mm
vic
probe
cdna
ad
reaction
mix
give
final
volum
uracildna
glycosylas
use
elimin
pcr
carri
contamin
previou
pcr
reaction
amplif
profil
optim
real
time
pcr
system
appli
biosystem
follow
one
cycl
decontamin
min
one
cycl
denatur
min
follow
cycl
amplif
cycl
number
fluoresc
signal
background
ct
proport
initi
log
concentr
target
dna
run
standard
curv
creat
rang
serial
dilut
hrv
dna
plasmid
standard
quantif
determin
normal
result
basi
spectrophotometr
analysi
nm
amplif
data
analyz
sequenc
detect
system
softwar
appli
biosystem
nucleotidenucleotid
blast
search
short
nucleotid
sequenc
perform
nation
center
biotechnolog
inform
nation
librari
medicin
web
site
wwwncbinlmnihgovblast
confirm
primer
pair
use
amplifi
follow
hrv
sequenc
access
number
amplifi
virus
pathogen
human
neg
control
number
precaut
undertaken
prevent
occurr
falseposit
result
run
includ
control
reaction
lack
templat
notempl
control
test
presenc
contamin
gener
nonspecif
amplif
product
assay
condit
use
posit
control
presenc
cellular
gapdh
transcript
analys
intern
control
marker
sensit
assay
primer
sequenc
gapdh
design
use
softwar
oligoperfecttm
design
invitrogen
within
exon
forward
primer
exon
revers
primer
report
tabl
coeffici
variat
sampl
quantifi
repeat
measur
calcul
descript
statist
express
absolut
valu
percentag
median
appropri
chisquar
test
appli
analyz
result
clinic
specimen
statist
analysi
perform
use
commerci
avail
softwar
med
calc
version
pvalu
consid
statist
signific
paramet
assess
repeat
test
serial
logarithm
dilut
plasmid
standard
cover
rang
log
number
genom
copi
plasmid
prepar
use
dilut
determin
spectrophotometri
nm
pcr
amplif
ct
valu
cross
point
amplif
curv
preset
threshold
fluoresc
detect
individu
dilut
step
plot
initi
viru
copi
number
lead
typic
standard
curv
amplif
effici
defin
standard
curv
slope
gener
three
four
consist
replic
measur
correl
coeffici
r
indic
linear
ct
valu
plot
standard
curv
r
index
higher
actual
sensit
assay
determin
lowest
standard
dilut
consist
detect
replic
reaction
frequenc
found
copyreact
linear
quantifi
copi
standard
dilut
copyreact
detect
frequenc
copyreact
frequenc
limit
detect
copyreact
effici
reaction
consid
accept
fall
rang
ideal
effici
realtim
rtpcr
assay
reproduc
express
coeffici
variat
cv
valu
concentr
furthermor
intra
interassay
variabl
evalu
differ
concentr
rang
plasmid
copi
within
singl
run
n
differ
run
experi
n
cv
valu
ct
report
tabl
quantif
hrv
highli
reproduc
copi
variabl
studi
analys
sampl
test
duplic
five
experi
result
quantif
reveal
median
cv
analyt
specif
rtpcr
assay
determin
test
coxsackieviru
type
atcc
atcc
atcc
echoviru
type
atcc
atcc
atcc
enteroviru
type
atcc
atcc
atcc
atcc
human
parainfluenza
virus
piv
atcc
piv
atcc
piv
atcc
influenza
virus
influenza
viru
atcc
atcc
influenza
b
viru
atcc
human
respiratori
syncyti
viru
rsva
atcc
human
adenoviru
atcc
atcc
atcc
herp
simplex
viru
atcc
human
cytomegaloviru
atcc
epsteinbarr
viru
atcc
human
coronaviru
type
atcc
atcc
streptococcu
pneumonia
atcc
legionella
pneumophila
atcc
mycoplasma
pneumonia
atcc
chlamydia
pneumonia
atcc
none
result
posit
thu
indic
method
specif
hrv
examin
dynam
rang
hrv
rna
quantif
rtpcr
serial
dilut
plasmid
standard
rang
copiesreact
carri
rtpcr
assay
abl
quantifi
hrv
rna
copiesreact
dynam
rang
copiesreact
r
obtain
linear
regress
analysi
without
dilut
high
load
sampl
viral
load
clinic
specimen
investig
duplic
reaction
appropri
extern
standard
prepar
effici
viral
rna
detect
clinic
sampl
possibl
presenc
polymeras
inhibitor
monitor
use
intern
control
describ
section
materi
method
control
permit
appropri
correct
calcul
viral
copi
number
quantif
viral
load
slope
yaxi
intercept
yaxi
intercept
point
standard
curv
intersect
ordin
indic
theoret
detect
limit
reaction
reveal
ct
expect
presenc
singl
target
molecul
sampl
correspond
standard
curv
ct
target
viru
amplif
use
accord
follow
equat
po
invers
log
ct
ys
po
number
viru
copi
equival
pcr
prior
amplif
result
hrv
quantif
summar
tabl
briefli
hrv
posit
bal
specimen
obtain
mani
patient
particular
sampl
immunocompromis
patient
sampl
immunocompet
patient
p
ns
viral
load
genom
equival
geq
ml
immunocompet
patient
rang
geqml
median
immunocompromis
patient
consid
discharg
diagnosi
pneumonia
respiratori
insuffici
exacerb
preexist
bronchopneumopathi
pneumopathi
signific
differ
preval
immunocompet
immunocompromis
patient
hrv
also
detect
one
sampl
obtain
routin
followup
one
lung
allograft
recipi
three
case
transplant
complic
result
clinic
sampl
main
featur
patient
posit
hrv
report
tabl
raticl
describ
develop
inhous
rt
realtim
pcr
assay
quantif
hrv
rna
clinic
sampl
realtim
pcr
assay
describ
close
system
postamplif
manipul
amplicon
requir
advantag
system
includ
reduc
turnaround
time
minimis
potenti
carryov
contamin
abil
close
scrutinis
assay
perform
thu
repres
suitabl
tool
routin
diagnost
virolog
use
extern
standard
curv
quantif
reli
upon
titrat
ident
amplifi
templat
relat
sampl
matrix
within
experiment
run
howev
approach
may
suffer
uncontrol
unmonitor
intertub
variat
thu
experi
describ
semiquantit
despit
suboptim
approach
fluoresc
data
gener
collect
pcr
cycl
span
linear
amplif
portion
reaction
fluoresc
signal
accumul
dna
proport
emiss
fluoresc
chemistri
temperatur
depend
data
gener
acquir
per
cycl
temperatur
order
monitor
amplicon
yield
ct
sampl
specif
fluoresc
valu
compar
similar
data
collect
seri
standard
calcul
standard
curv
determin
ct
depend
upon
sensit
abil
instrument
discrimin
specif
fluoresc
background
nois
concentr
natur
fluorescencegener
compon
amount
templat
initi
present
realtim
pcr
offer
signific
improv
viral
load
quantif
wide
dynam
rang
accommod
least
eight
copi
nucleic
acid
templat
made
possibl
data
chosen
linear
phase
amplif
condit
optim
rather
endpoint
final
amount
amplicon
could
affect
inhibitor
poorli
optimis
reaction
condit
satur
inhibitori
pcr
byproduct
doublestrand
amplicon
result
take
data
endpoint
may
exist
relationship
initi
templat
final
amplicon
concentr
realtim
pcr
studi
viral
load
present
lower
inter
intraassay
variabl
comparison
convent
pcr
equival
higher
analyt
sensit
comparison
tradit
viral
cultur
convent
singleround
nest
pcr
inde
pcr
method
significantli
improv
diagnosi
hrv
infect
howev
report
could
overestim
due
choic
smaller
target
amplifi
effici
due
use
differ
improv
primer
realtim
assay
use
softwar
design
optimis
primer
oligoprob
common
increas
sensit
broad
dynam
rang
combin
possibl
quantifi
templat
sampl
contain
wide
rang
concentr
clinic
specimen
avoid
need
dilut
amplicon
prior
convent
detect
repetit
assay
use
dilut
sampl
first
result
fall
outsid
detect
limit
perform
rt
realtim
pcr
develop
studi
examin
differ
concentr
hrv
rna
found
sensit
minimum
cutoff
detect
copyreact
linear
copi
sensit
defin
lowest
concentr
hrv
rna
quantifi
frequenc
found
copiesreact
assay
reproduc
high
median
interassay
variabl
intraassay
variabl
rang
rang
respect
thu
superior
obtain
studi
assay
develop
studi
base
primer
amplifi
viral
genom
highli
conserv
among
entero
rhinovirus
therefor
mani
pcr
protocol
amplifi
also
enterovirus
assay
result
abl
amplifi
hrv
sequenc
confirm
blast
search
amplifi
virus
pathogen
human
particular
enterovirus
studi
develop
rt
realtim
pcr
assay
detect
hrv
respiratori
specimen
howev
assay
develop
optim
basi
standard
amplif
profil
appli
biosystem
real
time
pcr
system
thu
allow
simultan
process
clinic
specimen
differ
virus
potenti
involv
respiratori
tract
infect
evalu
clinic
specimen
confirm
occurr
hrv
infect
lower
respiratori
tract
bal
specimen
result
posit
although
preval
infect
tend
higher
specimen
obtain
immunocompromis
patient
differ
reach
statist
signific
well
signific
associ
discharg
diagnosi
found
regard
taken
account
specimen
one
present
coinfect
least
anoth
respiratori
viru
includ
herpesvirus
hsv
ebv
cmv
human
metapneumoviru
human
coronaviru
human
bocaviru
parainfluenza
virus
influenza
virus
adenovirus
rsv
data
shown
hrv
shed
immunocompromis
host
could
prolong
comparison
immunocompet
one
thu
lead
onset
sever
complic
well
suggest
associ
acut
reject
lung
transplant
recipi
studi
multipl
sampl
avail
particular
lung
transplant
recipi
howev
repeat
posit
found
thu
prevent
possibl
evalu
issu
suggest
need
studi
similarli
signific
associ
found
occurr
exacerb
preexist
bronchopneumopati
associ
acut
exacerb
asthma
chronic
obstruct
pulmonari
diseas
respiratori
viral
pathogen
particularli
hrv
well
recogn
lack
associ
found
studi
could
due
small
number
thu
prevent
us
evalu
issu
conclus
rt
realtim
pcr
assay
develop
studi
could
repres
use
tool
diagnos
hrv
infect
quantifi
viral
load
could
applic
routin
diagnost
workup
upper
well
lower
respiratori
tract
diseas
avail
quantit
approach
detect
hrv
rna
could
repres
use
tool
investig
epidemiolog
clinic
role
hrv
clinic
context
involv
immunocompromis
host
particular
lung
transplant
recipi
associ
exacerb
preexist
bronchopneumopathi
particular
relat
viral
load
sever
durat
asthma
exacerb
